MedPath

Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)

A Comparative Study on Efficacy and Safety of add-on Sulforaphane or rTMS to Escitalopram for Major Depressive Disorder With Poor Response to Initial Treatment

Phase 4
Conditions
Major Depressive Disorder
Interventions
Dietary Supplement: Escitalopram+Sulforaphane
Device: Escitalopram+rTMS
First Posted Date
2021-12-06
Last Posted Date
2021-12-06
Lead Sponsor
Shanghai Mental Health Center
Target Recruit Count
180
Registration Number
NCT05145270
Locations
🇨🇳

Shanghai Mental Health Center, Shanghai, China

Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

Phase 4
Recruiting
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2021-08-23
Last Posted Date
2024-03-13
Lead Sponsor
Nova Scotia Health Authority
Target Recruit Count
400
Registration Number
NCT05017311
Locations
🇨🇦

University of British Columbia, Vancouver, British Columbia, Canada

🇨🇦

University of Calgary, Calgary, Alberta, Canada

🇨🇦

Queen's University, Kingston, Ontario, Canada

and more 4 locations

Aβ Dynamics in LLMD

Phase 4
Recruiting
Conditions
Alzheimer Disease
Major Depressive Disorder
Interventions
First Posted Date
2021-08-13
Last Posted Date
2024-08-29
Lead Sponsor
NYU Langone Health
Target Recruit Count
90
Registration Number
NCT05004987
Locations
🇺🇸

Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States

🇺🇸

NYU Langone Health, New York, New York, United States

Adjunctive Game Intervention for Anhedonia in MDD Patients

Not Applicable
Completed
Conditions
Depression
Interventions
Behavioral: Game intervention
First Posted Date
2021-07-26
Last Posted Date
2024-08-21
Lead Sponsor
Central South University
Target Recruit Count
50
Registration Number
NCT04977232
Locations
🇨🇳

The Second Xiangya Hospital of Central South University, Changsha, China

Serum Concentrations of Antidepressant Drugs in Pregnant Women - a Naturalistic Study

Completed
Conditions
Pregnancy
Antidepressive Agents
Pharmacokinetics
Interventions
First Posted Date
2021-03-19
Last Posted Date
2021-03-19
Lead Sponsor
Linkoeping University
Target Recruit Count
81
Registration Number
NCT04806230
Locations
🇸🇪

Linköping University, Linköping, Sweden

Mirtazapine in Cancer-related Poly-symptomatology

Phase 3
Terminated
Conditions
Cancer
Neoplasm Metastasis
Neoplasms
Interventions
First Posted Date
2021-02-21
Last Posted Date
2023-06-08
Lead Sponsor
Hospices Civils de Lyon
Target Recruit Count
1
Registration Number
NCT04763135
Locations
🇫🇷

Hôpitaux universitaires de Strasbourg, Strasbourg, France

🇫🇷

Centre Hospitalier Lyon Sud, Pierre-Bénite, France

🇫🇷

Centre Hospitalier Universitaire de Clermont-Ferrand, Cébazat, France

and more 8 locations

Antidepressant Response in Older Adults With Comorbid PTSD and MDD

Phase 4
Terminated
Conditions
Post Traumatic Stress Disorder
Major Depressive Disorder
Interventions
First Posted Date
2021-01-06
Last Posted Date
2022-05-11
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
1
Registration Number
NCT04697693
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)

Phase 4
Recruiting
Conditions
Anxiety
Interventions
First Posted Date
2020-11-10
Last Posted Date
2024-08-29
Lead Sponsor
University of Cincinnati
Target Recruit Count
132
Registration Number
NCT04623099
Locations
🇺🇸

University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, Cincinnati, Ohio, United States

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

Phase 3
Completed
Conditions
Depressive Disorder, Major
Interventions
First Posted Date
2020-07-17
Last Posted Date
2023-12-22
Lead Sponsor
Biogen
Target Recruit Count
440
Registration Number
NCT04476030
Locations
🇺🇸

Sage Investigational Site, Bellevue, Washington, United States

Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea

First Posted Date
2020-06-24
Last Posted Date
2024-12-09
Lead Sponsor
Pfizer
Target Recruit Count
370212
Registration Number
NCT04446039
Locations
🇰🇷

Pfizer, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath